These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30822354)

  • 1. Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma.
    Rao D; van Berkel A; Piscaer I; Young WF; Gruber L; Deutschbein T; Fassnacht M; Beuschlein F; Spyroglou A; Prejbisz A; Hanus K; Eisenhofer G; Manelli M; Canu L; Lenders JWM; Bancos I; Timmers HJLM
    J Clin Endocrinol Metab; 2019 Sep; 104(9):3812-3820. PubMed ID: 30822354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
    Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
    Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compared to
    Kroiss AS; Uprimny C; Shulkin BL; Frech A; Tilg H; Gasser RW; Sprinzl GM; Gruber L; Thomé C; Plangger C; Url C; Fraedrich G; Virgolini IJ
    Ann Nucl Med; 2017 Jun; 31(5):357-365. PubMed ID: 28349331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.
    Wiseman GA; Pacak K; O'Dorisio MS; Neumann DR; Waxman AD; Mankoff DA; Heiba SI; Serafini AN; Tumeh SS; Khutoryansky N; Jacobson AF
    J Nucl Med; 2009 Sep; 50(9):1448-54. PubMed ID: 19690028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
    Ilias I; Chen CC; Carrasquillo JA; Whatley M; Ling A; Lazúrová I; Adams KT; Perera S; Pacak K
    J Nucl Med; 2008 Oct; 49(10):1613-9. PubMed ID: 18794260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy.
    Furuta N; Kiyota H; Yoshigoe F; Hasegawa N; Ohishi Y
    Int J Urol; 1999 Mar; 6(3):119-24. PubMed ID: 10226821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging.
    Nakatani T; Hayama T; Uchida J; Nakamura K; Takemoto Y; Sugimura K
    Oncol Rep; 2002; 9(6):1225-7. PubMed ID: 12375024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation.
    Bhatia KS; Ismail MM; Sahdev A; Rockall AG; Hogarth K; Canizales A; Avril N; Monson JP; Grossman AB; Reznek RH
    Clin Endocrinol (Oxf); 2008 Aug; 69(2):181-8. PubMed ID: 18394016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas: a prospective study.
    Lumachi F; Tregnaghi A; Zucchetta P; Cristina Marzola M; Cecchin D; Grassetto G; Bui F
    Nucl Med Commun; 2006 Jul; 27(7):583-7. PubMed ID: 16794519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraindividual comparison of 123I-mIBG SPECT/MRI, 123I-mIBG SPECT/CT, and MRI for the detection of adrenal pheochromocytoma in patients with elevated urine or plasma catecholamines.
    Derlin T; Busch JD; Wisotzki C; Schoennagel BP; Bannas P; Papp L; Klutmann S; Habermann CR
    Clin Nucl Med; 2013 Jan; 38(1):e1-6. PubMed ID: 22996238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pheochromocytoma in internal medicine: distinctive features and place of 123I MIBG scintigraphy].
    Noblet-Dick M; Grunenberger F; Brunot B; Jaeck D; Schlienger JL
    Rev Med Interne; 2003 Jun; 24(6):358-65. PubMed ID: 12814824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of 123I-MIBG Scintigraphy in Paraganglioma.
    Milardovic R; Corssmit EP; Stokkel M
    Neuroendocrinology; 2010; 91(1):94-100. PubMed ID: 19786729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of
    Jaiswal SK; Sarathi V; Malhotra G; Hira P; Shah R; Patil VA; Dalvi A; Prakash G; Lila AR; Shah NS; Bandgar T
    J Pediatr Endocrinol Metab; 2021 Jan; 34(1):109-119. PubMed ID: 33180042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The utility of metaiodobenzylguanidine (MIBG) scintigraphy in patients with pheochromocytoma.
    Greenblatt DY; Shenker Y; Chen H
    Ann Surg Oncol; 2008 Mar; 15(3):900-5. PubMed ID: 18193324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases.
    Kawashima A; Sone M; Inagaki N; Okamoto K; Tsuiki M; Izawa S; Otsuki M; Okamura S; Ichijo T; Katabami T; Takeda Y; Yoshimoto T; Naruse M; Tanabe A
    Endocrine; 2021 Oct; 74(1):155-162. PubMed ID: 34272648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.